secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0000950170-23-027059
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome shareholders approve 2023 Employee Stock Purchase Plan and elect Mark Saad as director
--------------------------------------------------------------------------------

- Shareholders approved ESPP with 27.3M for, 357k against; 1.1M shares reserved for purchases at 85% of FMV.
- Mark Saad elected Class II director with 17.7M votes for, 10.1M withheld; 6.6M broker non-votes.
- Ratification of Ernst & Young as auditor passed with 34.1M for, 113k against.
- Non-binding advisory vote on executive compensation approved with 26.6M for, 629k against.
- ESPP allows payroll deductions of 1-15% of compensation; offering periods typically 12 months as of June 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023027059/0000950170-23-027059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023027059/axsm-20230602.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer